View Clinical Trial (Medical Research Study)
Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon: A Randomized Study
| City: |
|
Chicago |
| State: |
|
Illinois |
| Zip Code: |
|
60611 |
| Conditions: |
|
Multiple Sclerosis |
| Purpose: |
|
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most
cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms
between flares. Over years or decades, virtually all cases transition into a progressive
disease in which insidious and slow neurologic deterioration occurs with or without acute
flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating
therapies, while immune based therapies are generally ineffective in patients with a
progressive clinical course. This clinical course and response to immune suppression, as
well as neuropathology and neuroimaging studies, suggest that disease progression is
associated with axonal atrophy. Disability correlates better with measures of axonal
atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to
be effective, need to be started early in the disease course while MS is predominately an
immune-mediated and inflammatory disease. While current immune based therapies delay
disability, no intervention has been proven to prevent progressive disability. We propose,
as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of
cyclophosphamide and rATG versus FDA approved standard of care (i.e. interferon, copaxone,
or mitoxantrone) in patients with inflammatory (relapsing) MS despite treatment with
interferon.
|
| Study Summary: |
|
To assess the efficacy of autologous PBSCT versus FDA approved standard of care ( i.e.
interferon, copaxone, or mitoxantrone) for inflammatory multiple sclerosis failing
interferon therapy. The endpoints to be considered in this study are:
2.1 Primary Endpoint:
Disease progression, defined as a 1 point increase in the EDSS on consecutive evaluations at
least 6 months apart and not due to a non-MS disease process. Patients will be followed for
5 years after randomization.
2.2 Secondary Endpoints:
1. Number of relapses, defined as acute neurologic deterioration occurring after
engraftment and lasting more than 24 hours, accompanied by objective worsening on
neurological examination that are documented by a blinded neurologist and not explained
by fever, infection, stress or heat -related pseudoexacerbation. Supportive
confirmation by enhancement on MRI is preferred but not mandatory. We recognize that
blinding during the first year will be compromised by patient hair loss but efforts
will be made to mask hair loss by covering the heads of study patients during their
first year neurology assessments.
2. Ambulation index
3. Twenty-five foot timed walk
4. Nine hole PEG test
5. PASAT- 3 second and PASAT - 2 second
6. MRI enhancing lesions and T1 and T2 burden of disease per CombiRx MRI protocol
7. SF-36 and MSQOL
8. Scripps NRS
9. Survival
|
| Criteria: |
|
Inclusion Criteria:
1. Age between18-55, inclusive.
2. Diagnosis of MS using McDonald criteria of clinically definite MS (Appendix I).
3. An EDSS of 2.0 to 6.0 (Appendix II).
4. Inflammatory disease despite treatment with standard disease modifying therapy
including at least 6 months of interferon or copaxone. Inflammatory disease is
defined based on both MRI (gadolinium enhancing lesions) and clinical activity (acute
relapses *treated with IV high dose corticosteroids). Minimum disease activity
required for failure is defined as: a) two or more clinical relapses with documented
neurologic changes within the year prior to the study, or b) one *steroid treated
clinical relapse within the year prior to study and evidence on MRI of active
inflammation (i.e., gadolinium enhancement) within the last 12 months on an occasion
separate from the clinical relapse (3 months before or after the clinical relapse).
Exclusion criteria:
1. Any illness that in the opinion of the investigators would jeopardize the ability of
the patient to tolerate aggressive chemotherapy.
2. Prior therapy with mitoxantrone
3. Prior history of malignancy except localized basal cell, squamous skin cancer or
carcinoma in situ of the cervix. Other malignancies for which the patient is judged
to be cured, such as head and neck cancer, or breast cancer will be considered on an
individual basis.
4. Positive pregnancy test.
5. Inability or unwillingness to pursue effective means of birth control. Effective
birth control is defined as 1) refraining from all acts of vaginal intercourse
(ABSTINENCE); 2) consistent use of birth control pills; 3) injectable birth control
methods (Depo-provera, Norplant); 4) tubal sterilization or male partner who has
undergone vasectomy; 5) placement of an IUD (intrauterine device); or 6) use, with
every act of intercourse, of diaphragm with contraceptive jelly and/or condoms with
contraceptive foam.
6. Failure to willingly accept or comprehend irreversible sterility as a side effect of
therapy.
7. FEV1/FVC < 60% of predicted after bronchodilator therapy (if necessary).
8. DLCO < 50% of predicted (for the transplant arm).
9. Resting LVEF < 50 %.
10. Bilirubin > 2.0 mg/dl.
11. Serum creatinine > 2.0 mg/dl.
12. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron
compounds/medications.
13. Presence of metallic objects implanted in the body that would preclude the ability of
the patient to safely have MRI exams.
14. Diagnosis of primary progressive MS.
15. Diagnosis of secondary progressive MS
16. Platelet count < 100,000/ul, WBC < 1,500 cells/mm3.
17. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance
with treatment or informed consent impossible.
18. Active infection except asymptomatic bacteriuria.
19. Use of natalizumab within the previous 6 months.
|
| NCT ID: |
|
NCT00273364 |
| Primary Contact: |
|
Principal Investigator
Richard Burt, MD
Northwestern University
Dzemila Spahovic, MD
Phone: 312-908-0059
Email: d-spahovic@northwestern.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Chicago, Illinois 60611
United States
Dzemila Spahovic, MD
Phone: 312-908-0059
Email: d-spahovic@northwestern.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|